Combining Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer
Author Information
Author(s): Cascinu S, Silva R R, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi M A, Fusco V, Luporini G, Cellerino R, Catalano G
Primary Institution: Division of Medical Oncology, Azienda Ospedaliera ‘Ospedale S Salvatore’, Pesaro, Italy
Hypothesis
Can the combination of gemcitabine and 5-fluorouracil improve treatment outcomes in advanced pancreatic cancer patients?
Conclusion
The combination of gemcitabine and 5-fluorouracil showed a clinical benefit in over half of the patients with advanced pancreatic cancer.
Supporting Evidence
- 51% of patients experienced a clinical benefit from the treatment.
- Median survival for all patients was 7 months.
- No grade 3-4 gastrointestinal or hematological toxicity was recorded.
Takeaway
Doctors tested two cancer drugs together to see if they could help people with a tough kind of cancer, and it worked for some of them.
Methodology
A multi-institutional phase II study with a two-stage design was conducted, enrolling 54 symptomatic patients who received gemcitabine and 5-fluorouracil.
Potential Biases
The non-randomized nature may introduce bias in the results.
Limitations
The non-randomized design of the study suggests caution in interpreting the results.
Participant Demographics
All 54 patients were symptomatic with issues like pain and weight loss.
Statistical Information
Confidence Interval
95% CI 38–64%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website